Search

Displaying results 1501 - 1510 of 7535 in total
  1. Drug

    Anthralin

    go.drugbank.com/drugs/DB11157
    Approved

    It is important to consider that the drug is relatively innocuous, yet effective, and systemic side effects have not been observed with this anthralin, in contrast to a wide variety of systemic and topical … Salicylic acid is frequently added to anthralin to augment the stability of anthralin and to increase its penetration and efficacy [L1979].

  2. Drug

    Alefacept

    go.drugbank.com/drugs/DB00092
    ApprovedWithdrawn

    Produced by CHO cells, mW is 91.4 kD. … Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of

  3. Drug

    Calcitriol

    go.drugbank.com/drugs/DB00136
    ApprovedInvestigationalNutraceutical

    In addition to promoting fatty acid synthesis and inhibiting lipolysis, calcitriol has been demonstrated to increase energy efficiency by suppressing UCP2 expression, which is modulated by signaling pathways … Calcitriol plays a role in plasma calcium regulation in concert with parathyroid hormone (PTH) by enhancing absorption of dietary calcium and phosphate from the gastrointestinal tract, promoting renal

    Products: RO-CAL 0.25mcg
  4. Drug

    Fenproporex

    go.drugbank.com/drugs/DB01550
    ApprovedIllicitWithdrawn

    It is listed as an illicit substance in many countries due to addiction issues and listed as a prohibited substance by the World Anti-Doping Agency. … effects are less notorious than with some other agents such as diethylpropion and mazindol. [7] In the United States fenproporex was never approved by the FDA for clinical use due to a lack of efficacy

  5. Target

    Serum paraoxonase/arylesterase 2

    go.drugbank.com/bio_entities/BE0009921
    TargetHumans

    Capable of hydrolyzing lactones and a number of aromatic carboxylic acid esters. Has antioxidant activity. Is not associated with high density lipoprotein. Prevents LDL lipid peroxidation, reverses the oxidation of mildly oxidized LDL, a...

    Synonyms: A-esterase 2, Aromatic esterase 2
  6. Drug

    Marnetegragene autotemcel

    go.drugbank.com/drugs/DB17595
    Approved

    [L56116, A275467] Allogeneic hematopoietic stem cell transplant is a curative option but is limited by issues such as donor availability, a high incidence of graft-versus-host disease, and graft failure … These modified cells differentiate to express functional CD18 protein, restoring leukocyte adhesion and extravasation.

  7. Drug

    Zuranolone

    go.drugbank.com/drugs/DB15490
    ApprovedInvestigational

    [A260791] Zuranolone was approved by the FDA on August 4th, 2023, and it is currently the only approved treatment for women with postpartum depression. … binding to a non-benzodiazepine site on the receptor.

  8. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    [A189207] Antagonism of the CGRP pathway has become an attractive target for migraine therapy as, unlike the triptans, oral CGRP antagonists have no observed vasoconstrictive properties and are therefore … [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and

  9. Drug

    Xylometazoline

    go.drugbank.com/drugs/DB06694
    Approved

    Xylometazoline works by binding to alpha (α)-adrenergic receptors to cause vasoconstriction of nasal blood vessels. … [A228508] Xylometazoline is available in over-the-counter (OTC) nasal sprays or drops to temporarily relieve nasal congestion due to cold, hay fever or other respiratory allergies.

    Products: OLYNTH 0.05% N O KONSERVIE, OLYNTH 0.1% N O KONSERVIER
  10. Drug

    Lumacaftor

    go.drugbank.com/drugs/DB09280
    ApprovedInvestigational

    [A20343] Improvements in lung function (ppFEV1) were found to be statistically significant, but minimal, with only a 2.6-3.0% change from baseline with more than 70% of patients failing to achieve an absolute … [A18395] The next most common mutation, G551D, affecting 4-5% of CF patients worldwide, is characterized as a missense mutation, whereby there is sufficient amount of protein at the cell surface, but opening